# Definium Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Definium Therapeutics, Inc.). ## Overview Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based medicines for brain health disorders. The company’s lead program is DT120 ODT, which it is advancing through Phase 3 trials in generalized anxiety disorder (GAD) and major depressive disorder (MDD). ## Products & services • DT120 ODT for generalized anxiety disorder (GAD) • DT120 ODT for major depressive disorder (MDD) • Other brain health product candidates in preclinical/clinical development • Clinical development, regulatory, and commercialization planning • cGMP manufacturing and supply of product candidates - **Lead clinical candidate** (0%) — DT120 ODT is the company’s lead oral disintegrating tablet program being advanced in late-stage trials. - **Pipeline product candidates** (0%) — Additional psychedelic or neuropsychiatric candidates under research and development. - **Clinical development services** (0%) — Internal and external trial design, execution, and data generation for regulatory approval. - **Manufacturing and supply** (0%) — cGMP production, packaging, and supply of investigational product for trials and launch readiness. - **Commercialization preparation** (0%) — Market access, medical affairs, and launch planning for any approved product. - DT120 ODT for generalized anxiety disorder (GAD) - DT120 ODT for major depressive disorder (MDD) - Other brain health product candidates in development - Clinical trial execution and regulatory submissions - cGMP manufacturing and supply chain management ## Customers The company does not yet sell approved products, so its current “customers” are primarily clinical trial sites, investigators, regulators, and research partners that support development. If approved, its end customers would be physicians, pharmacies, and patients in psychiatry and brain health markets, with distribution constrained by controlled-substance rules. - **Clinical trial ecosystem** (primary) — Research sites, investigators, and CRO-like partners that execute studies and generate data for approval. - **Regulatory stakeholders** (primary) — FDA and other regulators that determine whether product candidates can advance to market. - **Psychiatry prescribers** (secondary) — Psychiatrists and other physicians who would prescribe DT120 ODT if approved for GAD or MDD. - **Patients with brain health disorders** (secondary) — Adults with anxiety or depression who may use the therapy if it reaches commercialization. - **Controlled-substance distributors and pharmacies** (secondary) — DEA-registered supply chain participants needed to distribute any scheduled product. - Clinical trial sites and investigators running Phase 3 studies - Regulators and ethics bodies reviewing trial and approval packages - Wholesale distributors and pharmacies if products are approved - Physicians treating GAD and MDD patients - Patients seeking novel psychiatric treatments ## Geography Definium is headquartered in New York, with a Canadian corporate base in British Columbia and a U.S. subsidiary in Delaware. Its operating footprint also includes offices in San Diego, Durham, and Madison, reflecting a U.S.-centric development model with cross-border corporate structure. Because it is pre-commercial, geography matters mainly through where trials are run, where management and R&D are located, and where future distribution rules will apply. - Headquartered in New York, United States - Canadian parent company incorporated in British Columbia - Wholly owned U.S. subsidiary in Delaware - Offices in San Diego, Durham, and Madison - No disclosed revenue geography because the company has no product sales ## Strategy The company’s strategy is to advance psychedelic-based psychiatry with scientific rigor, centered on completing Phase 3 trials for DT120 ODT in GAD and MDD. It is also preparing for the operational steps needed after approval, including manufacturing, commercialization, and patient access, while preserving liquidity through the development cycle. - **Advance DT120 ODT through Phase 3** (short-term) — Late-stage data is the main value driver and the key step toward approval. - **Prepare for regulatory and commercial execution** (medium-term) — Approval would require manufacturing, distribution, and market access readiness. - **Maintain financing flexibility** (short-term) — The company has no product revenue and depends on external capital to fund R&D. - Complete Phase 3 trials in GAD and MDD - Build evidence for efficacy, safety, and convenience - Prepare manufacturing and supply for potential launch - Develop commercialization and patient access capabilities - Preserve cash runway through staged R&D execution ## Risks Definium is a pre-revenue clinical-stage company, so its value depends on successful trial outcomes, regulatory approval, and access to capital. Its product candidates are controlled substances, which adds distribution, prescribing, and public-perception risk on top of the usual clinical, manufacturing, and commercialization uncertainties in biotech. - **Clinical development failure** [critical] — The company’s lead value driver depends on positive Phase 3 results in GAD and MDD. - **Capital dependence** [high] — The company has operating losses, no product revenue, and ongoing R&D cash burn. - **Regulatory and controlled-substance restrictions** [high] — Approval, scheduling, DEA registration, and state monitoring rules can slow uptake. - **Product liability and professional indemnity** [high] — Any adverse events in trials or post-approval could trigger claims and reputational damage. - **Public perception of psychedelics** [medium] — Negative publicity may reduce physician willingness to prescribe and patient acceptance. - No approved products means no commercial revenue yet - Phase 3 trials may fail or produce inconclusive results - Additional financing may be needed before commercialization - Controlled-substance status can limit prescribing and distribution - Adverse publicity around psychedelics could hurt adoption ## Accounting The most important accounting issue is that the company has no product revenue, so operating results are driven by R&D expense, stock-based compensation, and financing-related items rather than sales recognition. Investors should also watch fair-value and debt accounting for financing instruments, plus estimates around clinical and legal contingencies, because these can move reported losses and balance-sheet strength materially. - **Research and development expense timing** — Affects operating loss comparability and cash burn analysis - **Stock-based compensation** — Inflates non-cash operating expense and reduces comparability - **Debt and warrant accounting** — Can affect net loss, leverage presentation, and dilution analysis - **Contingent liabilities and product liability reserves** — May change reported liabilities and earnings if estimates shift - No revenue recognition yet because no approved products are sold - R&D expense is the main operating cost and can be lumpy by trial stage - Stock-based compensation affects reported losses and non-cash burn - Loan and warrant accounting can create interest, fair-value, or dilution effects - Contingencies and product liability estimates may affect future provisions --- *Last updated: 2026-04-28T20:01:39.422485+00:00*